Eli Lilly and Co. stock gains as Foundayo demand expands

Published on 09/22/2026 at 11:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eli Lilly and Co. stock closed at USD 1,164.89 on September 21, 2026, up 1.04 percent. Foundayo generated USD 98 million in second-quarter sales.

Fotorealistischer Blick auf eine generische Plasma-Etch-Maschine mit lila Plasmaschein durch das Sichtfenster im Halbleiter-Reinraum — Lam Research US5324571083 generische Plasma Etch Maschine mit lila Plasma im modernen Reinraum sichtbar, Illustration mit AI erstellt.

Eli Lilly and Co. (ISIN US5324571083) closed at USD 1,164.89 on the NYSE on September 21, 2026, up 1.04 percent from the previous session. The immediate catalyst is Foundayo, the company's oral obesity treatment, as Eli Lilly prepares a USD 6.5 billion Houston manufacturing site.

Foundayo reaches new patients

According to CNBC on September 21, 2026, Eli Lilly CEO Dave Ricks said one-third of new oral GLP-1 patients were starting on Foundayo. That compares with nearly one in four new starts cited during the company's August earnings update, giving the launch a concrete sequential improvement.

The treatment generated USD 98 million in sales during the second quarter of 2026, its first three-month period on the US market, according to CNBC. The Houston facility is expected to become operational by 2030 and will also produce active ingredients for medicines in cardiometabolic health, oncology, immunology and neuroscience.

Medicare broadens the market

Medicare coverage that began on July 1, 2026, has already brought about 700,000 US seniors into GLP-1 treatment, Ricks told CNBC on September 21, 2026. About 70 percent of those new patients are using Lilly medicines, while the broader second-quarter 2026 GLP-1 market share cited by the company was about 61 percent.

The comparison matters because Foundayo entered the US market behind Novo's oral product. Lilly's rising share of new oral starts therefore addresses the launch concern directly, while the manufacturing investment targets the supply capacity needed for international expansion. The counter-factor is competition: CNBC reported that Novo's pill is generally viewed as somewhat more effective for weight loss, leaving execution and prescription growth central to Lilly's valuation.

Stock remains below yearly high

The NYSE quote reached an intraday high of USD 1,170.90 on September 21, 2026, while the 52-week range was USD 712.05 to USD 1,292.65. Market capitalization stood at USD 1.09 trillion and volume at 4.54 million shares in the latest MarketBeat snapshot dated September 21, 2026.

Eli Lilly and Co. stock therefore traded USD 127.76 below the 52-week high at the September 21 close, while remaining USD 452.84 above the low. The market is weighing expanding access and Foundayo's improving launch against the premium valuation and Novo's established position in oral obesity treatment.

NYSE price sets the reference

Eli Lilly and Co. stock closed at USD 1,164.89 on the NYSE on September 21, 2026, with a daily gain of 1.04 percent. The quoted market capitalization was USD 1.09 trillion as of September 21, 2026.